[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 577 Introduced in Senate (IS)]
<DOC>
117th CONGRESS
2d Session
S. RES. 577
Designating April 2022 as ``Parkinson's Awareness Month''.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
April 6, 2022
Ms. Stabenow (for herself and Mr. Thune) submitted the following
resolution; which was referred to the Committee on the Judiciary
_______________________________________________________________________
RESOLUTION
Designating April 2022 as ``Parkinson's Awareness Month''.
Whereas Parkinson's disease--
(1) affects 1,000,000 individuals in the United States;
(2) is the second most common neurodegenerative disease in the world;
(3) is believed to be caused by a combination of genetic and
environmental factors; and
(4) is the 14th leading cause of death in the United States, according
to the Centers for Disease Control and Prevention;
Whereas it is estimated that, by the year 2037, the number of individuals with
Parkinson's disease in the United States will nearly double, and the
disease will cost the United States at least $79,000,000,000 annually;
Whereas the symptoms of Parkinson's disease can include dementia and cognitive
impairment, tremors, slowness of movement, ``freezing'' in place,
inability to walk and maintain balance, speech difficulties, depression,
losing the ability to swallow, and a variety of other symptoms;
Whereas there are millions of family caregivers, friends, and loved ones whose
lives are greatly affected by Parkinson's disease; and
Whereas more research, education, and community support services are needed to--
(1) find better treatments and a cure for Parkinson's disease; and
(2) maintain dignity for those living with the disease today: Now,
therefore, be it
Resolved, That the Senate--
(1) designates April 2022 as ``Parkinson's Awareness
Month'';
(2) supports the goals and ideals of Parkinson's Awareness
Month;
(3) continues to support research to find better treatments
and a cure for Parkinson's disease;
(4) recognizes the individuals living with Parkinson's
disease who participate in vital clinical trials to advance the
knowledge of the disease; and
(5) commends the dedication of organizations, volunteers,
researchers, and millions of individuals across the country
working to improve the quality of life of people living with
Parkinson's disease and their families.
<all>